Back to mobile site

Gilead Sciences (GILD) Upcoming Data Looks More Likely To Be Positive After Ph3 filgotinib - Piper Jaffray

September 12, 2018 8:49 AM EDT Send to a Friend
Piper Jaffray analyst, Tyler Van Buren, reiterated his Overweight rating on shares of Gilead Sciences (NASDAQ: GILD) and believes that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login